Abstract
BackgroundThe novel compound 1a is one of the isoflavone fatty acid esters. In order to investigate the anti-obesity effect of compound 1a and its potential mechanism of influence in adipocyte differentiation, Obese male C57BL/6J mice induced by high-fat diet (HFD) and rat preadipocytes (3T3-L1 cell) were used.MethodsAfter 4-week HFD induction, the obese model was made successfully. After treatment with compound 1a, mice plasma biochemistry parameters were analyzed. In addition, mice hepatic tissue slice was observed. In in vitro research, 3T3-L1 cell differentiation by Oil-Red-O staining and adipocyte apoptosis was detected by flow cytometry.ResultsThe in vivo results implied that compound 1a significantly decreased the body weight, white adipose tissue weight of obesity mice(p < 0.05), reduced leptin and TG in plasma(p < 0.05), elevated HDL-C in serum(p < 0.05). The in vitro results suggested that compound 1a could significantly suppress the adipocyte viability and lipid accumulation in the differentiation of preadipocyte, and induce apoptosis in both preadipocytes and mature adipocytes(p < 0.05).ConclusionCompound 1a regulates serum lipid profiles, decreases adipose tissue mass and body weight gain by inducing adipocyte apoptosis in high fat diet induced mice. Thus, it may be used to treat obese patients with hypercholesterolemia and hypertriglyceridemia.
Highlights
The novel compound 1a is one of the isoflavone fatty acid esters
Body mass (BM) and fat mass After 4 weeks' induction, mice fed with high-fat diet (HFD) had 5.3% higher body weights compared with normal group fed with low fat diet (LFD) (p < 0.05)
As compound 1a dosage doubled, the weight loss compared with model group increased
Summary
In order to investigate the anti-obesity effect of compound 1a and its potential mechanism of influence in adipocyte differentiation, Obese male C57BL/6J mice induced by high-fat diet (HFD) and rat preadipocytes (3T3-L1 cell) were used. Though there are dozens of potential targets for anti-obesity, only three agents, sibutramine (Reductil® or Meridia®), an appetite suppressant orlistat (Xenical®), an inhibitor of fat absorption and rimonaban, a CB1 antagonist, have been introduced into the market during recent years [3]. The programmed differentiation of preadipocytes into adipocytes involves several stages related to obesity [15]. For these reasons, many research efforts have been conducted in 3T3-L1 cells to search for new health benefit foods/agents for obesity or weight control. Potential therapeutic agents that inhibit adipogenesis or increase adipocyte death by apoptosis could be important tools in preventing obesity [16]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
